• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在 Graves 眼病存在的情况下治疗甲状腺。

Treating the thyroid in the presence of Graves' ophthalmopathy.

机构信息

University of Southern Denmark, Odense, Denmark.

出版信息

Best Pract Res Clin Endocrinol Metab. 2012 Jun;26(3):313-24. doi: 10.1016/j.beem.2011.09.005.

DOI:10.1016/j.beem.2011.09.005
PMID:22632368
Abstract

The etiology of Graves' orbitopathy (GO) remains enigmatic. Optimal therapeutic choices for the hyperthyroidism associated with Graves' disease (GD) in the presence of GO remain controversial. Whether antithyroid drugs (ATDs), radioiodine (RAI), or thyroidectomy should be favored in such patients remains debated. Pre-therapy variables such as ethnicity, sex, age, thyroid function, level of TSH-receptor antibodies and smoking behavior influence response to therapy. Among the most important management goals are restoring euthyroidism and abstaining from smoking. On average, ATDs and thyroidectomy - independent of extent - do not influence the natural course of GO. RAI can cause de novo development or progression of GO, which is largely preventable with oral steroid prophylaxis. In patients with mild GO, the thyroid treatment is largely independent of GO. Moderate to severe GO should be treated promptly. Deciding whether, in the latter, GD is better treated with ATDs, RAI, or surgery, is based more on expert opinion than on evidence. It is clear that in the individual patient a number of factors, not addressed in any trial, influence the final choice of therapy for GD, including concern of developing or negatively affecting pre-existing GO. Evidently, there is room for improving therapy of GO. Progress using novel drugs such as rituximab, which might potentially influence positively both GD and GO, are impatiently awaited.

摘要

格雷夫斯眼病(GO)的病因仍然是个谜。对于伴有 GO 的格雷夫斯病(GD)患者,甲状腺功能亢进的最佳治疗选择仍存在争议。在这些患者中,是否应该优先选择抗甲状腺药物(ATD)、放射性碘(RAI)还是甲状腺切除术仍存在争议。治疗前的变量,如种族、性别、年龄、甲状腺功能、促甲状腺激素受体抗体水平和吸烟行为,会影响治疗反应。最重要的管理目标之一是恢复甲状腺功能正常并戒除吸烟。平均而言,ATD 和甲状腺切除术——无论范围如何——都不会影响 GO 的自然病程。RAI 可导致 GO 的新发或进展,这在很大程度上可以通过口服类固醇预防来预防。对于轻度 GO 患者,甲状腺治疗在很大程度上与 GO 无关。对于中度至重度 GO,应立即进行治疗。对于后者,是选择 ATD、RAI 还是手术治疗 GD,更多的是基于专家意见而不是证据。很明显,在个体患者中,许多在任何试验中都未涉及的因素会影响 GD 治疗的最终选择,包括对发生或对先前存在的 GO 产生负面影响的担忧。显然,GO 的治疗还有改进的空间。人们急切地期待着使用利妥昔单抗等新型药物来治疗 GO,这些药物可能会对 GD 和 GO 产生积极影响。

相似文献

1
Treating the thyroid in the presence of Graves' ophthalmopathy.在 Graves 眼病存在的情况下治疗甲状腺。
Best Pract Res Clin Endocrinol Metab. 2012 Jun;26(3):313-24. doi: 10.1016/j.beem.2011.09.005.
2
The dilemma of how to manage Graves' hyperthyroidism in patients with associated orbitopathy.Graves 病伴发眼眶病患者中如何治疗格雷夫斯甲亢的困境。
J Clin Endocrinol Metab. 2011 Mar;96(3):592-9. doi: 10.1210/jc.2010-2329. Epub 2010 Dec 29.
3
Time course of Graves' ophthalmopathy after total thyroidectomy alone or followed by radioiodine therapy: a 2-year longitudinal study.单纯甲状腺全切除术与甲状腺全切除术后放射性碘治疗 Graves 眼病的时间进程:一项 2 年的纵向研究。
Endocrine. 2012 Apr;41(2):320-6. doi: 10.1007/s12020-011-9559-x. Epub 2011 Nov 16.
4
Clinical update: treatment of hyperthyroidism in Graves' ophthalmopathy.临床最新进展:格雷夫斯眼病中甲状腺功能亢进症的治疗
Pediatr Endocrinol Rev. 2010 Mar;7 Suppl 2:193-7.
5
The tale of radioiodine and Graves' orbitopathy.放射性碘与格雷夫斯眼病的故事。
Thyroid. 2010 Jul;20(7):785-93. doi: 10.1089/thy.2010.1640.
6
Cohort study on radioactive iodine-induced hypothyroidism: implications for Graves' ophthalmopathy and optimal timing for thyroid hormone assessment.放射性碘致甲状腺功能减退症的队列研究:对格雷夫斯眼病的影响和甲状腺激素评估的最佳时机。
Thyroid. 2013 May;23(5):620-5. doi: 10.1089/thy.2012.0258.
7
Prevention of Graves' ophthalmopathy.格雷夫斯眼病的预防。
Best Pract Res Clin Endocrinol Metab. 2012 Jun;26(3):371-9. doi: 10.1016/j.beem.2011.09.004.
8
Radioiodine therapy (RAI) for Graves' disease (GD) and the effect on ophthalmopathy: a systematic review.放射性碘治疗(RAI)用于格雷夫斯病(GD)及其对眼病的影响:一项系统评价。
Clin Endocrinol (Oxf). 2008 Dec;69(6):943-50. doi: 10.1111/j.1365-2265.2008.03279.x. Epub 2008 Apr 21.
9
Total thyroidectomy (Tx) versus thionamides (antithyroid drugs) in patients with moderate-to-severe Graves' ophthalmopathy - a 1-year follow-up: study protocol for a randomized controlled trial.全甲状腺切除术(Tx)与硫代酰胺类药物(抗甲状腺药物)治疗中重度格雷夫斯眼病患者的疗效比较——1年随访:一项随机对照试验的研究方案
Trials. 2018 Sep 15;19(1):495. doi: 10.1186/s13063-018-2876-0.
10
Changes in graves' ophthalmopathy after radioiodine and anti-thyroid drug treatment of Graves' disease from 2 prospective, randomized, open-label, blinded end point studies.来自两项前瞻性、随机、开放标签、盲终点研究的格雷夫斯病患者在接受放射性碘和抗甲状腺药物治疗后格雷夫斯眼病的变化。
Exp Clin Endocrinol Diabetes. 2014 Jan;122(1):1-6. doi: 10.1055/s-0033-1358484. Epub 2013 Nov 7.

引用本文的文献

1
A systematic review of euthyroid Graves' disease (Review).正常甲状腺功能的格雷夫斯病的系统评价(综述)
Exp Ther Med. 2021 Nov;22(5):1346. doi: 10.3892/etm.2021.10781. Epub 2021 Sep 22.
2
Total thyroidectomy (Tx) versus thionamides (antithyroid drugs) in patients with moderate-to-severe Graves' ophthalmopathy - a 1-year follow-up: study protocol for a randomized controlled trial.全甲状腺切除术(Tx)与硫代酰胺类药物(抗甲状腺药物)治疗中重度格雷夫斯眼病患者的疗效比较——1年随访:一项随机对照试验的研究方案
Trials. 2018 Sep 15;19(1):495. doi: 10.1186/s13063-018-2876-0.
3
Insulin-like Growth Factor-I Receptor and Thyroid-Associated Ophthalmopathy.
胰岛素样生长因子-I受体与甲状腺相关性眼病
Endocr Rev. 2019 Feb 1;40(1):236-267. doi: 10.1210/er.2018-00066.
4
A questionnaire survey on the management of Graves' orbitopathy in China: A comparison with Europe and Latin-America.中国Graves眼病管理的问卷调查:与欧洲和拉丁美洲的比较
Chronic Dis Transl Med. 2015 Jul 7;1(2):117-123. doi: 10.1016/j.cdtm.2015.06.001. eCollection 2015 Jun.
5
[Graves' ophthalmopathy].[格雷夫斯眼病]
Ophthalmologe. 2016 Apr;113(4):349-64; quiz 465-6. doi: 10.1007/s00347-016-0239-3.
6
Thyroid eye disease.甲状腺眼病
CMAJ. 2013 Jun 11;185(9):797. doi: 10.1503/cmaj.121815. Epub 2013 Apr 2.